Scisparc Ltd (SPRC)

Scisparc Ltd (SPRC) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $2.6M; returns 1 day -9.2%, 1 week -35.9%, 1 year -97.0%.

Scisparc Ltd. is a clinical-stage pharmaceutical company transitioning into a diversified life sciences entity. Historically, its primary focus has been on developing a pipeline of cannabinoid-based therapies for central nervous system (CNS) disorders, including SCI-110 for Tourette syndrome and Alzheimer's, SCI-210 for autism spectrum disorder, and SCI-160 for pain management.

Groups SPRC belongs to

• Recent Reverse Splits
• Israel Companies
• Pharmaceuticals
• Biotechnology
• Clinical Stage Biotech
• CNS Disorders
• Cannabis
• Life Sciences
• Drug Discovery
• Clinical Stage

SPRC financial model: income statement, cash flow and balance sheet